Anja Pišlar

Dr. Anja Pišlar

University of Ljubljana, Faculty of Pharmacy, Aškerčeva 7, 1000 Ljubljana, Slovenia
orcid

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
7 April 2022 in Biomedicine & Pharmacotherapy
Verified
Journal Article
Open access
SCSandra Cetin
Sandra Cetin
DKDamijan Knez
Damijan Knez
SGStanislav Gobec
Stanislav Gobec
JKJanko Kos
Janko Kos
APAnja Pišlar
Anja Pišlar
Neurodegenerative diseases are severely debilitating conditions characterized primarily by progressive neuronal loss and impairment of the nervous system. Alzheimer's and Parkinson's diseases are the most common neurodegenerative disorders, and their impact is increasing as average life expectancy increases worldwide. Although the underlying mechanisms of both progressive diseases have been extensively studied, we still lack a comprehensive understanding of the molecular basis of both diseases. Current therapeutic options do not slow the progression of the diseases and only provide symptom relief. Cell models that resemble the characteristics of the disease in question are important in drug discovery projects because they provide information about the therapeutic benefits of drugs under development. Here, we review current in vitro cell models used to study the molecular basis of Alzheimer's and Parkinson's disease focusing on their potential for discovering of disease-modifying therapeutics to combat neurodegenerative diseases. We discuss phenotypic screening as an important approach for identifying novel therapeutic molecules. Advances in the development of cell-based assays for drug discovery are discussed, ranging from simple monoculture cell models to high-throughput three-dimensional cell models. Finally, we critically present the limitations of cell models and the caveats encountered in drug discovery to find effective treatment for neurodegenerative diseases.

15 November 2013 in Molecular Neurobiology
Verified
Journal Article
Closed access
PDF file
APAnja Pišlar
Anja Pišlar
JKJanko Kos
Janko Kos

1 December 2018 in Seminars in Cancer Biology
Verified
Journal Article
Closed access
APAnja Pišlar
Anja Pišlar
AJAnahid Jewett
Anahid Jewett
JKJanko Kos
Janko Kos

1 March 2017 in Neuropharmacology
Verified
Journal Article
Closed access
APAnja Pišlar
Anja Pišlar
BNBiljana Božić Nedeljković
Biljana Božić Nedeljković
NZNace Zidar
Nace Zidar
JKJanko Kos
Janko Kos

1 July 2014 in Neuropharmacology
Verified
Journal Article
Closed access
APAnja Pišlar
Anja Pišlar
NZNace Zidar
Nace Zidar
DKDanijel Kikelj
Danijel Kikelj
JKJanko Kos
Janko Kos

30 November 2021 in Biomolecules
Verified
Journal Article
Open access
PDF file
APAnja Pišlar
Anja Pišlar
LBLara Bolčina
Lara Bolčina
JKJanko Kos
Janko Kos
Neuroinflammation, which is mediated by microglia and astrocytes, is associated with the progression of neurodegenerative diseases. Increasing evidence shows that activated microglia induce the expression and secretion of various lysosomal cathepsins, particularly during the early stage of neuroinflammation. This trigger signaling cascade that aggravate neurodegeneration. To date, most research on neuroinflammation has focused on the role of cysteine cathepsins, the largest cathepsin family. Cysteine cathepsins are primarily responsible for protein degradation in lysosomes; however, they also play a role in regulating a number of other important physiological and pathological processes. This review focuses on the functional roles of cysteine cathepsins in the central nervous system during neuroinflammation, with an emphasis on their roles in the polarization of microglia and neuroinflammation signaling, which in turn causes neuronal death and thus neurodegeneration.